Compare Novavax Inc (NVAX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Wheaton Precious Metals Corp — how do they compare? Novavax Inc trades at $12.59 (market cap $1.82B), while Wheaton Precious Metals Corp trades at $138.93 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is far larger — about 33.6× Novavax Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Wheaton Precious Metals Corp for 66 Days on average.
| NVAX | WPM | |
|---|---|---|
Market Cap | $1.82B | $61.17B |
Volume | 6,198,505 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $12.56 | $165.72 |
52-Week Low | $6.22 | $94.37 |
Typical Hold Time | 59 Days | 66 Days |
Enterprise Value | $1.39B | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% on the day, amid a bearish technical signal. The company reported record H1 2026 revenues and beat EPS estimates for three consecutive quarters, with strong profitability margins (gross margin 75.25%, net margin 64.66%). Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive given robust earnings momentum and analyst consensus (80% buy ratings, $164.80 price target). Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock offers exposure to precious metals with high margins but trades at premium valuations (P/E 29.94, P/S 19.36), requiring confidence in delivery of projected growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
